Cancer drug design targeted by COSMIC's new 3-D system

COSMIC-3D, the most comprehensive system for exploring cancer mutations in three dimensions, is launched today by COSMIC, based at the Wellcome Trust Sanger Institute, in collaboration with Astex Pharmaceuticals, Cambridge, UK. With extensive colourful and helpful visualisations, the new resource can help identify and characterise drug targets as well as support the design of new therapeutics for cancer.
The new tool is set to change the way researchers interact with genomic mutations in order to identify new cancer drug targets.

Available at http://cancer.sanger.ac.uk/cosmic3d, COSMIC-3D provides interactive 3D visualisations of more than 8,000 human proteins displaying cancer mutations. It enables researchers to develop a clearer understanding of which mutations are implicated in cancer progression, and how these mutations impact molecular structure and function. 

Significantly, COSMIC-3D displays known and predicted drug binding sites within the protein structure. This displays alongside binding sites with predictions of how likely a pocket is to be successful as a drug target, enhancing the exploration and identification of how mutations impact therapeutic targets.

COSMIC-3D has been designed to directly assist pharmaceutical development. The new resource utilises COSMIC - Catalogue of Somatic Mutations in Cancer, the world's largest expert-curated human cancer mutation database - and also incorporates structural information from the Worldwide Protein Data Bank (wwPDB).

Credit: Wellcome Trust Sanger Institute

Explore further

New statistical analysis reveals thousands of rare mutations linked with cancer

Citation: Cancer drug design targeted by COSMIC's new 3-D system (2017, May 10) retrieved 17 October 2019 from https://medicalxpress.com/news/2017-05-cancer-drug-cosmic-d.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more